Kaye Edward M. MD 4
4 · Stoke Therapeutics, Inc. · Filed Dec 10, 2025
Insider Transaction Report
Form 4
Kaye Edward M. MD
Director
Transactions
- Sale
Common Stock
2025-12-08$31.44/sh−3,825$120,253→ 58,729 total - Sale
Common Stock
2025-12-08$32.52/sh−8,274$269,070→ 50,455 total - Sale
Common Stock
2025-12-08$33.10/sh−1,331$44,062→ 49,124 total
Footnotes (4)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.90 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 2 and 3 of this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.95 per share, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.25 per share, inclusive.